Access to Medicines
CSL continues to work with international and national partners to deliver life-saving therapies to patients across the world. Our longstanding partnerships with the World Federation of Hemophilia and the Jeffrey Modell Foundation continue to be strong.
In 2017, Seqirus contributed US$3.7 million to the WHO Pandemic Influenza Preparedness Framework, which aims to enhance program infrastructure and pandemic readiness in low- and middle-income countries. Also in 2016/2017, CSL Behring provided US$5 million in product and/or financial support directly to U.S. patients through our patient assistance programs. These access programs support qualified patients who are uninsured, underinsured or cannot afford their prescribed therapy.
CSL marked World Hemophilia Day in April 2017 by contributing more than four million international units (IUs) of treatments for hemophilia A and/or von Willebrand disease. The contribution is part of CSL Behring’s three-year promise to provide more than 10 million IUs of specialty biotherapeutics to the World Federation of Hemophilia (WFH) to treat hemophilia in the developing world. In 2016, CSL Behring’s product donations to the WFH supported hemophilia patients in Cambodia, Cameroon, Jamaica, Mali, Nicaragua, Philippines and Venezuela.
As part of our global commitment, Seqirus has agreed to donate 10 percent of influenza vaccine output in real time to the World Health Organization for deployment to developing countries in the event of a global pandemic emergency. Seqirus also contributed US$3.7 million to the WHO Pandemic Influenza Preparedness Framework, which aims to enhance program infrastructure and pandemic readiness in low- and middle-income countries.
The Jeffrey Modell Foundation is devoted to early and precise diagnosis, meaningful treatments and, ultimately, cures for those with primary immunodeficiency (PI). CSL Behring has been a partner to this organization and its important work of creating PI diagnostic and research centers since its inception over 30 years ago. In March 2017, the foundation announced its plans to open its first PI network and center in Africa, with CSL Behring a proud sponsor. The North African Network will join over 200 similar sites in the Jeffrey Modell Centers Network around the world. These centers offer advanced diagnostic evaluations to patients with suspected primary immune deficiencies and our support helps CSL to deliver on our promise to PI patients. In Africa, it’s estimated that the diagnosis rate of PI, a life threatening condition, is only about 0.3 percent.